PARIS--(BUSINESS WIRE)-- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® ...

Abstracts represent exciting research progress across four cancers where patients have limited treatment options "While a robust Phase 3 clinical trial program in gastric/gastroesophageal junction ...

Dr. Dwight Owen presents the first update to the ASCO living guideline on stage IV NSCLC with driver alterations. He identifies the latest trials that informed this update, and the updated ...

SYDNEY, AUSTRALIA, May 27, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (PRRUF) (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy ...

Tarah J. Ballinger, MD, discusses several trials in metastatic breast cancer (mBC) being presented at the upcoming 2022 American Society of Clinical Oncology Annual Meeting. The first study data that ...

BOSTON & SEATTLE--(BUSINESS WIRE)--Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that the clinical strategy ...

A drug combination targeting multiple mutant versions of cancer’s ‘death star’ protein has shown promise in a small, early-phase clinical trial for some patients with advanced lung, ovarian and ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Today, Sarah Cannon Research Institute announced that it will highlight its latest cancer research insights through more than 140 abstracts and presentations at the ...

Out of 239 phase III trial abstracts, 90 trials involving 49,721 patients met the inclusion criteria. Of these, 36 (40%) could not be graded by ESMO-MCBS, mainly because of nonsignificant results.

Uncommon histologies are over-represented among high-risk breast cancer (BC) and denote an area with limited trial data and of significant unmet medical need. To better understand trial outcomes in ...